Oxford BioTherapeutics
June 16, 2025
Company Presentation
Oncology
At Oxford BioTherapeutics, our oncology discovery capabilities span a diverse range of modalities, all underpinned by our proprietary target discovery platform OGAP®-Verify that drives our mission to develop breakthrough cancer therapies. OGAP®-Verify is the world’s largest proprietary membrane protein abundance database, containing data on approximately 7,000 membrane proteins across most solid and hematological malignancies, as well as normal tissues. Data has been generated using quantitative mass spectrometry directly on patient cancer biopsies and normal tissues. High sensitivity allows detection of membrane proteins at 50 copies-per-cell on the cell’s surface. The sensitivity surpasses IHC and de-risks selection of new oncology targets. Average abundance of the tumour antigen target in patient tissue samples can be estimated allowing drug modality and payload selection.
Company HQ City:
San Jose
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2004
Lead Product in Development:
Multiple antibody based therapies in multiple stages of preclinical and clinical development
CEO
Dr. Christian Rohlff
Year Founded
2004
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
Many across multiple oncology indications
What is your next catalyst (value inflection) update?
March 2025
Website
https://www.oxfordbiotherapeutics.com/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}